Kevin R. Sayer Sells 7,000 Shares of DexCom Inc. (DXCM) Stock
DexCom Inc. (NASDAQ:DXCM) CEO Kevin R. Sayer sold 7,000 shares of the company’s stock in a transaction on Friday, October 14th. The shares were sold at an average price of $81.87, for a total transaction of $573,090.00. The sale was disclosed in a filing with the SEC, which is available at the SEC website.
Kevin R. Sayer also recently made the following trade(s):
- On Wednesday, September 14th, Kevin R. Sayer sold 7,000 shares of DexCom stock. The shares were sold at an average price of $91.79, for a total transaction of $642,530.00.
- On Monday, August 15th, Kevin R. Sayer sold 7,000 shares of DexCom stock. The shares were sold at an average price of $90.78, for a total transaction of $635,460.00.
Shares of DexCom Inc. (NASDAQ:DXCM) opened at 82.52 on Wednesday. The stock has a 50 day moving average of $89.12 and a 200-day moving average of $78.97. The company’s market capitalization is $6.92 billion. DexCom Inc. has a one year low of $47.92 and a one year high of $96.38.
DexCom (NASDAQ:DXCM) last posted its quarterly earnings results on Tuesday, August 2nd. The medical device company reported ($0.24) EPS for the quarter, missing analysts’ consensus estimates of ($0.12) by $0.12. The company earned $137.30 million during the quarter, compared to analyst estimates of $132.48 million. DexCom had a negative return on equity of 19.68% and a negative net margin of 16.42%. The company’s revenue for the quarter was up 47.3% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($0.05) earnings per share. On average, equities analysts forecast that DexCom Inc. will post ($0.57) earnings per share for the current fiscal year.
DXCM has been the subject of several research analyst reports. Jefferies Group reissued a “positive” rating and issued a $98.00 price target on shares of DexCom in a report on Friday, July 22nd. Canaccord Genuity reissued a “buy” rating and issued a $95.00 price target on shares of DexCom in a report on Wednesday, July 13th. BMO Capital Markets initiated coverage on shares of DexCom in a report on Friday, September 16th. They issued an “outperform” rating and a $112.00 price target for the company. Leerink Swann reissued an “outperform” rating and issued a $90.00 price target on shares of DexCom in a report on Wednesday, July 20th. Finally, JPMorgan Chase & Co. reissued a “buy” rating and issued a $100.00 price target on shares of DexCom in a report on Wednesday, August 3rd. One research analyst has rated the stock with a sell rating, four have assigned a hold rating, twelve have assigned a buy rating and one has given a strong buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus price target of $95.40.
Large investors have recently bought and sold shares of the company. BNP Paribas Arbitrage SA boosted its stake in DexCom by 3,320.0% in the third quarter. BNP Paribas Arbitrage SA now owns 1,197 shares of the medical device company’s stock worth $105,000 after buying an additional 1,162 shares during the last quarter. Bellwether Investment Group LLC bought a new stake in DexCom during the second quarter worth approximately $119,000. Bank of Montreal Can bought a new stake in DexCom during the second quarter worth approximately $134,000. Capstone Asset Management Co. bought a new stake in DexCom during the third quarter worth approximately $205,000. Finally, Private Bank & Trust Co. bought a new stake in DexCom during the third quarter worth approximately $220,000. Institutional investors and hedge funds own 99.28% of the company’s stock.
DexCom Company Profile
Dexcom, Inc (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring systems for ambulatory use by people with diabetes and for use by healthcare providers for the treatment of people with and without diabetes. Its products include SEVEN PLUS, DexCom G4, DexCom G4 PLATINUM, DexCom Share System and DexCom G5 Mobile.
Receive News & Ratings for DexCom Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom Inc. and related companies with MarketBeat.com's FREE daily email newsletter.